Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Noa Dagan; Noam Barda; Tal Biron-Shental; Maya Makov-Assif; Calanit Key; Isaac S. Kohane; Miguel A. Hernán; Marc Lipsitch; Sonia Hernandez-Diaz; Ben Y. Reis; Ran D. Balicer

doi:10.1038/s41591-021-01490-8

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Noa Dagan, Noam Barda, Tal Biron-Shental, Maya Makov-Assif, Calanit Key, Isaac S. Kohane, Miguel A. Hernán, Marc Lipsitch, Sonia Hernandez-Diaz, Ben Y. Reis, Ran D. Balicer

Research output: Contribution to journal › Article › peer-review

Abstract

To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.

Original language	English
Pages (from-to)	1693-1695
Number of pages	3
Journal	Nature Medicine
Volume	27
Issue number	10
DOIs	https://doi.org/10.1038/s41591-021-01490-8
State	Published - Oct 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41591-021-01490-8

Cite this

@article{a9a450eb7b21407fa3814e450bee4e21,

title = "Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy",

abstract = "To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.",

author = "Noa Dagan and Noam Barda and Tal Biron-Shental and Maya Makov-Assif and Calanit Key and Kohane, {Isaac S.} and Hern{\'a}n, {Miguel A.} and Marc Lipsitch and Sonia Hernandez-Diaz and Reis, {Ben Y.} and Balicer, {Ran D.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2021",

month = oct,

doi = "10.1038/s41591-021-01490-8",

language = "English",

volume = "27",

pages = "1693--1695",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

AU - Dagan, Noa

AU - Barda, Noam

AU - Biron-Shental, Tal

AU - Makov-Assif, Maya

AU - Key, Calanit

AU - Kohane, Isaac S.

AU - Hernán, Miguel A.

AU - Lipsitch, Marc

AU - Hernandez-Diaz, Sonia

AU - Reis, Ben Y.

AU - Balicer, Ran D.

PY - 2021/10

Y1 - 2021/10

N2 - To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.

AB - To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.

UR - http://www.scopus.com/inward/record.url?scp=85114643001&partnerID=8YFLogxK

U2 - 10.1038/s41591-021-01490-8

DO - 10.1038/s41591-021-01490-8

M3 - Article

C2 - 34493859

AN - SCOPUS:85114643001

SN - 1078-8956

VL - 27

SP - 1693

EP - 1695

JO - Nature Medicine

JF - Nature Medicine

IS - 10

ER -

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this